Epic’s agent factory and the end of the middle layer: what health tech investors need to understand right now
Table of Contents
Section 1: What Epic Actually Announced (And Why It Matters More Than the Headline)
Section 2: The Market Position Problem – Epic’s Gravity Has Become Structural
Section 3: What Gets Killed, What Gets Squeezed, and What Gets Accelerated
Section 4: The Embedded Competitor Problem for Portfolio Companies
Section 5: Where the Real Opportunity Lives Post-Agent Factory
Section 6: Investment Theses That Need Recalibration
Abstract
This essay analyzes Epic’s HIMSS26 announcements – specifically Agent Factory, its no-code agentic AI builder – and the downstream implications for health tech entrepreneurs and investors. Key data points and themes:
- Epic holds 42.3% of the acute care EHR market by hospital count and 54.9% by bed count as of 2024
- Epic revenue grew from $4.9B (2023) to $5.7B (2024), with R&D spend historically running at ~50% of operating expense
- Agent Factory enables drag-and-drop, no-code AI agent orchestration for health systems – clinical, administrative, patient-facing
- The HIMSS26 lineup includes Art (clinical AI), Emmie (patient chatbot), Penny (rev cycle), and Forward (clinical trials management)
- Over 1,000 apps listed on Epic’s Showroom; 2,400+ called a live API in the last year
- The no-code capability compresses the technical moat previously held by AI middleware, workflow automation, and point-solution startups
- Viable investment zones post-Agent Factory: data layers Epic can’t own, cross-EHR interoperability plays, specialty-specific clinical decision support, and infrastructure bets upstream of Epic
- Several digital health categories warrant portfolio review – especially ambient documentation, administrative automation, and rev cycle AI in Epic-heavy customer bases
What Epic Actually Announced (And Why It Matters More Than the Headline)
Before getting into the so-what, it helps to be precise about what Epic showed up to HIMSS26 with, because the framing in most of the coverage undersells it. The headline is “Agent Factory” – a no-code, drag-and-drop environment that lets Epic customers build and orchestrate AI agents that can reason, decide, and execute steps autonomously across clinical and operational workflows. Phil Lindemann, Epic’s VP of data and research, described it plainly: their customers have ideas for where AI can help, and Agent Factory is how they bring those ideas to life without needing to call a vendor or write a line of code.
That one sentence should be circled by every health tech investor who has a portfolio company selling workflow automation to Epic-installed health systems. The historical pitch of many digital health startups has been some version of “we know what your Epic data means and we can do something useful with it.” Agent Factory is Epic’s answer that maybe the health system itself can do that now, on their own, with a visual builder, without writing a check to a startup. That may be an overstatement of what no-code actually delivers in year one – no-code tools have been around in other verticals for years and have not eliminated custom software – but the direction of travel is unmistakable.
Alongside Agent Factory, Epic rolled out a suite of named AI products at HIMSS26 that investors need to track individually. Art is Epic’s clinical AI assistant, with AI Charting already deployed across multiple outpatient specialties in Wisconsin. The pattern here follows Epic’s prior playbook: launch in-state first, prove it, scale it. Emmie is the patient-facing chatbot built into MyChart. Penny is the revenue cycle co-pilot. Forward is a clinical trials management system integrated directly with the rest of Epic’s platform, including its research discovery tools, covering end-to-end study management. First phases are available in 2026, full rollout in 2027.
Put these together and what you have is a company that has essentially announced it is building a full operating stack for health systems – not just the EHR, but clinical AI, patient engagement AI, revenue cycle AI, research management, and now a citizen developer environment for custom AI agents. For a company that reportedly invests up to 50% of operating expenses back into R&D, HIMSS26 represents the point where the outputs of that compounding investment are becoming visible all at once.
The Market Position Problem – Epic’s Gravity Has Become Structural
